Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYN-401
- Development stage
- Preclinical
- Lead developer
- Syndeio Biosciences
01
Overview
SYN-401 is a discovery-stage therapeutic candidate under development by Syndeio Biosciences. The program is part of the company's 'Novel synapse target' category, focusing on undisclosed biological targets within the synapse to treat neurological or neuropsychiatric conditions. While Syndeio's lead programs, such as zelquistinel and apimostinel, are NMDA receptor positive allosteric modulators, SYN-401 represents a distinct, novel approach within their pipeline. Specific details regarding its chemical modality, precise molecular target, and primary clinical indications have not yet been publicly disclosed by the developer.
Beyond the preview
Go deeper on SYN-401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYN-401.